Lifeboat Foundation

Type 1 diabetes is caused by insulin deficiency resulting from immune-mediated destruction of pancreatic beta cells. Its cause is multifactorial, with complex genetic factors and a strong influence of certain HLA types that probably indicates T-cell-mediated disease.1 Despite attempts to halt the autoimmune destruction of the pancreatic islet at disease onset with immunotherapeutic approaches, 1 recovery of pancreatic beta-cell function remains a challenge because type 1 diabetes is not reversible, even early in the disease.

Correspondence from The New England Journal of Medicine — STAT1 Gain of Function, Type 1 Diabetes, and Reversal with JAK Inhibition.

The majority of commercial chemicals that enter the market in the United States every year have insufficient health and safety data. For pesticides, the U.S. Environmental Protection Agency uses a variety of techniques to fill data gaps in order to evaluate chemical hazard, exposure and risk. Nonetheless, public concern over the potential threat that these chemicals pose has grown in recent years, along with the realization that traditional animal-testing methods are not pragmatic by means of speed, economics or ethics. Now, researchers at the George Washington University have developed a new computational approach to rapidly screen pesticides for safety, performance and how long they will endure in the environment. Moreover, and most importantly, the new approach will aid in the design of next-generation molecules to develop safer pesticides.

“In many ways, our tool mimics computational drug discovery, in which vast libraries of chemical compounds are screened for their efficacy and then tweaked to make them even more potent against specific therapeutic targets,” Jakub Kostal, an assistant professor of chemistry at GW and principal investigator on the project, said. “Similarly, we use our systems-based approach to modify pesticides to make them less toxic and more degradable, while, at the same time, making sure they retain good performance. It’s a powerful tool for both industry and regulatory agencies that can help design new, safer analogs of existing commercial agrochemicals, and so protect human life, the environment and industry’s bottom line.”

Using their model, the team analyzed 700 pesticides from the EPA’s pesticide registry. The model considered a pesticide’s likely persistence or degradation in the environment over time, its safety, and how well it performed at killing, repelling or controlling the target problem.

On Valentine’s Day 2022 in Havana, Cuba, I received the Soberana Plus booster shot, one of the island nation’s five homegrown COVID-19 vaccines. The jab had been a long time coming.

For the past year, I had been fixated on the idea of being injected with a made-in-Cuba coronavirus vaccine. While obviously not offering protection against the imperial machinations of my homeland and Cuba’s chief antagonist, the United States, the Cuban serums were at least being developed in the interest of global public health rather than pharmaceutical profit or “vaccine apartheid”, as World Health Organization (WHO) Director General Tedros Adhanom Ghebreyesus has described it.

The story of how I finally got my made-in-Cuba booster in Havana.

Continue reading “How to get a Cuban COVID jab in 1,000 easy steps” »

With batteries, motion sensors, and a microLED on board, Mojo lets me try out its first apps.

The Hubble Space Telescope has revealed a single star whose light has traveled for 12.9 billion years to Earth, having come from a universe just 900 million years old. It’s currently the most distant star known, and the team has dubbed it Earendel*.

The discovery is a huge jump, as the previous record-holder for more distant star existed in a universe 4 billion years old.

Continue reading “Looking Through Mojo Vision’s Newest AR Contact Lens” »

Reward maximisation is one strategy that works for reinforcement learning to achieve general artificial intelligence. However, deep reinforcement learning algorithms shouldn’t depend on reward maximisation alone.

Identifying dual-purpose therapeutic targets implicated in aging and disease will extend healthspan and delay age-related health issues.

AI is all that matters now, and reaching Agi before 2030 is all that matters for this decade.

A substantial percentage of the human clinical trials, including those evaluating investigational anti-aging drugs, fail in Phase II, a phase where the efficacy of the drug is tested. This poor success is in part due to inadequate target choice and the inability to identify a group of patients who will most likely respond to specific agents. This challenge is further complicated by the differences in the biological age of the patients, as the importance of therapeutic targets varies between the age groups. Unfortunately, most targets are discovered without considering patients’ age and being tested in a relatively younger population (average age in phase I is 24). Hence, identifying potential targets that are implicated in multiple age-associated diseases, and also play a role in the basic biology of aging, may have substantial benefits.

Identifying dual-purpose targets that are implicated in aging and disease at the same time will extend healthspan and delay age-related health issues – even if the target is not the most important in a specific patient, the drug would still benefit that patient.

Continue reading “Insilico identifies therapeutic targets implicated in aging using AI and hallmarks of aging framework” »

Great article by the great Steve Hill. One little thing:

“The life extension community unfortunately does have a reputation for being long on promises and short on delivery. With what is now decades of research, there are still no effective therapies against aging.”

Continue reading “Life Extension and Anti-Aging Have a Branding Problem” »

Despite a wealth of knowledge gained in the past three decades concerning the molecular underpinnings of Alzheimer’s disease (AD), progress towards obtaining effective, disease modifying therapies has proven to be challenging. In this manner, numerous clinical trials targeting the production, aggregation, and toxicity of beta-amyloid, have failed to meet efficacy standards. This puts into question the beta-amyloid hypothesis and suggests that additional treatment strategies should be explored. The recent emergence of CRISPR/Cas9 gene editing as a relatively straightforward, inexpensive, and precise system has led to an increased interest of applying this technique in AD. CRISPR/Cas9 gene editing can be used as a direct treatment approach or to help establish better animal models that more faithfully mimic human neurodegenerative diseases. In this manner, this technique has already shown promise in other neurological disorders, such as Huntington’s disease. The purpose of this review is to examine the potential utility of CRISPR/Cas9 as a treatment option for AD by targeting specific genes including those that cause early-onset AD, as well as those that are significant risk factors for late-onset AD such as the apolipoprotein E4 (APOE4) gene.

Keywords: Alzheimer’s disease, CRISPR/Cas9, Gene editing, Treatment, Huntington’s disease, iPSC neurons.

Alzheimer’s Disease (AD) is a progressive and fatal neurodegenerative disorder that primarily affects older adults and is the most common cause of dementia [1]. Currently it afflicts 5.5 million Americans and that number is expected to triple by 2050. At the present time, it is the third leading cause of death behind heart disease and cancer, with an estimated 700,000 Americans ages65 years will have AD when they die [2]. In addition, the cost of the disease is substantial with $259 billion health care dollars going to manage the disease currently, and by the middle of the century costs are predicted to soar over $1.2 trillion, which will completely bankrupt the healthcare system in the USA [3]. Worldwide, 47 million people live with dementia and that number is projected to increase to more than 131 million by 2050 with an estimated worldwide cost of US $818 billion [4].

In addition to its premium vacuums 0, hair styling products 0, and gale-force bathroom hand dryers, Dyson is also known for its air purifiers featuring a bladeless design that makes them quieter and safer, but also a glass HEPA filter inside that promises to remove 99.97% of unwanted air particles in a home like pollen, mold, bacteria, pollution, and odors. There’s even one that can eliminate formaldehyde. That’s great for when you’re at home or the office, but a four-foot tall purifier tethered to a power outlet offers no protection from pollution anywhere else.

The Dyson Zone is the company’s first personal air purification device, and it comes with headphones as a side dish. Trojan-horsed into the high-end bluetooth headset, the Zone offers a buffer of filtration between the wearer and the outside world. When worn out in public, users may feel a bit like Bane from Batman. There may be some awkward stares, but perhaps there will be fewer than expected, thanks to the presence of the headphones.

The company started working on the Zone six years ago. The initial protype was a “snorkel-like clean air mouthpiece paired with a backpack to hold the motor and inner workings,” according to a press release. The final product—over 500 iterations later—is a huge improvement when it comes to design and ergonomics. It still looks like it might take some time to get used to, though maybe less so in the era of Covid-19 than when Dyson’s engineers first started on it.